Nabriva plans to launch its first approved antibiotic, Xenleta lefamulin, in mid-September to treat community-acquired bacterial pneumonia, and the company has taken steps to facilitate Xenleta's adoption through negotiations with healthcare providers, payers and pharmacies.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,